Acute cellular rejection in small-bowel transplantation impairs NCR+ innate lymphoid cell subpopulation 3/interleukin 22 axis

RUMBO, CAROLINA; NACHMAN, FABIO; MEIER, DOMINIK; RUMBO, CAROLINA; NACHMAN, FABIO; MEIER, DOMINIK; PUCCI MOLINERIS, MELISA; FUXMAN, CLAUDIA; RUMBO, MARTÍN; PUCCI MOLINERIS, MELISA; FUXMAN, CLAUDIA; RUMBO, MARTÍN; GONZÁLEZ POLO, VIRGINIA; LOWESTEIN, CARLOS; GONDOLESI, GABRIEL; GONZÁLEZ POLO, VIRGINIA; LOWESTEIN, CARLOS; GONDOLESI, GABRIEL

TRANSPLANT IMMUNOLOGY

ELSEVIER SCIENCE BV

Lugar: Amsterdam; Año: 2020 vol. 60

0966-3274

Acute cellular rejection (ACR) remains as one of the main causes of graft loss and death in intestinal transplant (ITx) patients. ACR promotes intestinal injury, disruption of the mucosal barrier, bacterial translocation, and organ dysfunction. As epithelial regeneration is critical in reversing these consequences, the functional axis between the innate lymphoid cell subpopulation 3 (ILC3) and interleukin 22 plays an essential role in that process. Natural-cytotoxic-receptor?positive (NCR+) ILC3 cells have been demonstrated to induce intestinal-stem-cell proliferation along with an IL-22?dependent expansion of that population in several intestinal pathologies, though thus far not after ITx. Therefore, we intended to determine the impact of chronic immunosuppression and ACR on ILC3 cells and interleukin-22 (IL-22) production in the lamina propria after that intervention. Materials and methods: We compared biopsies from healthy volunteers with biopsies from ITx recipients without or with mild-to-moderate ACR, using flow cytometry and the quantitative-PCR. Results: NCR+ ILC3 cells were found to be unaffected by immunosuppression at different time points posttransplant when patients did not experience ACR, but were diminished upon the occurrence of ACR independently of the post-ITx time. Moreover, IL-22?expression levels were notably reduced in ACR. Conclusion: The NCR+-ILC3/IL-22 axis is impaired during ACR contributing to a delay in or lack of a complete and efficient epithelial regeneration. Thus, our findings reveal that IL-22 analogues could potentially be used as a new complementary therapeutic approach, in conjunction with immunosuppressant drugs, in order to promote mucosal regeneration upon ACR.